CommercialCoverageHigh impact
08.01.62h, Nivolumab (Opdivo®), Nivolumab and Hyaluronidase-nvhy (Opdivo Qvantig™)
Independence Blue Cross·Oncology, Pharmacy·Pharmacy
Effective date
Aug 24, 2026
We identified it
Aug 25, 2026
Summary
This is a brand-new policy (1 day old) establishing coverage and medical necessity criteria for Nivolumab (Opdivo®) and Nivolumab and Hyaluronidase-nvhy (Opdivo Qvantig™). The policy includes coverage guidelines, reimbursement positions, and medical necessity requirements effective immediately. Billing teams must obtain and review the full policy text to identify specific coverage restrictions, prior authorization requirements, and any billing code changes.
Action Required
By 2026-08-24: Billing team must immediately obtain and review the complete policy text at https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=08&FilterField2=MPSiteActivityLogYear&FilterValue2=2026#commercial-08-01-62h to identify: (1) specific HCPCS drug codes and billing codes affected; (2) prior authorization requirements; (3) medical necessity documentation criteria; (4) any coverage exclusions or limitations. Update billing system rules, encounter forms, and provider alerts accordingly. Communicate changes to oncology providers and billing staff. Without proper implementation, claims for Nivolumab products may be denied or delayed. Note: The summary information provided does not include the detailed clinical criteria, codes, or requirements—the full policy document must be reviewed immediately.